Natural history and treatment of HCV/HIV coinfection: Is it time to change paradigms?

详细信息    查看全文

• 作者：Joop E. Arends¹ ; ^&dagger ; ; ^{j.e.arends@umcutrecht.nl" class="auth_mail" title="E-mail the corresponding author} ; Faydra I. Lieveld¹ ; Lauke L. Boeijen¹ ; Clara T.M.M. de Kanter² ; Karel J. van Erpecum³ ; Dominique Salmon⁴ ; ^&dagger ; ; Andy I.M. Hoepelman¹ ; ^&dagger ; ; Tarik Asselah⁵ ; Andrew Ustianowski⁶
• 关键词：HCV ; hepatitis C virus ; HIV ; human immunodeficiency virus ; MSM ; men who have sex with men ; iv ; intravenous ; PegIFN伪 ; pegylated interferon-alfa ; RBV ; ribavirin ; SVR ; sustained virological response ; GT ; genotype ; DAA ; direct-acting antiviral ; NS3 ; nonstructural protein 3 ; SOF ; sofosbuvir ; LDV ; ledipasvir ; DAC ; daclatasvir ; CROI ; Conference on Retroviruses and Opportunistic Infections ; EASL ILC ; European Association for the Study of the Liver Study International Liver Conference ; cART ; combination
• 刊名：Journal of Hepatology
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：63
• 期：5
• 页码：1254-1262
• 全文大小：790 K

文摘

Evidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.